Platinum Doublet Chemotherapy
Sponsors
Bristol-Myers Squibb, Fondazione Ricerca Traslazionale, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, University of Miami
Conditions
Non Small Cell Lung CancerNon-Small-Cell Lung CancerNon-small-cell Lung Cancer Patients
Phase 2
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
CompletedNCT02659059
Start: 2016-02-15End: 2022-03-07Updated: 2023-04-05
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
RecruitingNCT05568212
Start: 2022-05-02End: 2027-05-31Target: 176Updated: 2025-12-01
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Not yet recruitingNCT06198907
Start: 2024-01-31End: 2027-12-31Target: 69Updated: 2024-01-10
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
RecruitingNCT06902272
Start: 2025-06-11End: 2029-06-11Target: 30Updated: 2025-07-22